Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BSA-based versus concentration-based cisplatin dosing for OVHIPEC in advanced ovarian cancer
NL-OMON56202Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cisplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Platinum concentration in tumor nodule at the end of HIPEC. Started Sep 2022; status: recruiting.
02
Drugs
cisplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON56202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56202.